万赛维的用法用量

Antiviral drugs for systemic use. It is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome and for the prevention of cytomegalovirus infection in high-risk solid organ transplant patients.

Standard dosage: Vancevir is administered orally and should be taken with food. Vansavir can be rapidly and massively converted into ganciclovir. The bioavailability of Vancevir as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, therefore the Vancevir dosage and usage instructions described below should be strictly adhered to.

1. Adult patients:

(1) Induction treatment of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets), taken twice a day for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity.

(2) Maintenance treatment of CMV retinitis: After induction therapy, or for patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

(3) Prevention of CMV infection in transplant patients:

①For kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation.

②For patients who have received a solid organ transplant other than kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

2. Special dosage guidelines:

(1) Patients with renal insufficiency: Serum creatinine or creatinine clearance levels should be closely monitored. See the instructions for details.

(2) Patients with severe leukopenia, neutropenia, anemia, thrombocytopenia and pancytopenia Cases of severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, myelosuppression and aplastic anemia have been observed in patients treated with Vancevir (and ganciclovir). Treatment with Vancevir should not be started if the absolute neutrophil count is less than 500/μl, the platelet count is less than 25,000/μl, or the hemoglobin is less than 8 g/dl.

(3) Patients undergoing hemodialysis: For patients undergoing hemodialysis (CrCl<10ml/min), no recommended dosage can be given. Therefore it cannot be used in such patients.